NO20015291L - Månedlige doser for behandling av Streptococcus pneumoniae- infeksjoner - Google Patents

Månedlige doser for behandling av Streptococcus pneumoniae- infeksjoner

Info

Publication number
NO20015291L
NO20015291L NO20015291A NO20015291A NO20015291L NO 20015291 L NO20015291 L NO 20015291L NO 20015291 A NO20015291 A NO 20015291A NO 20015291 A NO20015291 A NO 20015291A NO 20015291 L NO20015291 L NO 20015291L
Authority
NO
Norway
Prior art keywords
treatment
streptococcus pneumoniae
pneumoniae infections
monthly doses
monthly
Prior art date
Application number
NO20015291A
Other languages
English (en)
Other versions
NO20015291D0 (no
Inventor
Thomas Reeves Parr
Margaret Mary Wasilewski
Michael Lee Zeckel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20015291D0 publication Critical patent/NO20015291D0/no
Publication of NO20015291L publication Critical patent/NO20015291L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En fremgangsmåte for behandling av langtids forebygging av S. pneumoniae i mottakelige individer tilveiebringes hvori en høyst månedlig dose av N4-(4-klorfenyl)benzyl)A82846B, teicoplanin eller blanding derav, tilføres et mottakelig individ.
NO20015291A 1999-05-03 2001-10-29 Månedlige doser for behandling av Streptococcus pneumoniae- infeksjoner NO20015291L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13225899P 1999-05-03 1999-05-03
PCT/US2000/008737 WO2000066144A2 (en) 1999-05-03 2000-04-19 Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumoniae infections

Publications (2)

Publication Number Publication Date
NO20015291D0 NO20015291D0 (no) 2001-10-29
NO20015291L true NO20015291L (no) 2001-12-17

Family

ID=22453188

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015291A NO20015291L (no) 1999-05-03 2001-10-29 Månedlige doser for behandling av Streptococcus pneumoniae- infeksjoner

Country Status (29)

Country Link
EP (1) EP1175222B1 (no)
JP (1) JP2002543146A (no)
KR (1) KR100757165B1 (no)
CN (1) CN1349407A (no)
AR (1) AR023827A1 (no)
AT (1) ATE284702T1 (no)
AU (1) AU774647B2 (no)
BR (1) BR0010244A (no)
CA (1) CA2372790A1 (no)
CZ (1) CZ296127B6 (no)
DE (1) DE60016734T2 (no)
DZ (1) DZ3039A1 (no)
EA (1) EA004295B1 (no)
HK (1) HK1044707B (no)
HR (1) HRP20010808A2 (no)
HU (1) HUP0200940A3 (no)
IL (2) IL145582A0 (no)
MY (1) MY123542A (no)
NO (1) NO20015291L (no)
NZ (1) NZ514467A (no)
PE (1) PE20010292A1 (no)
PL (1) PL353444A1 (no)
SK (1) SK285970B6 (no)
SV (1) SV2002000065A (no)
TR (1) TR200103211T2 (no)
TW (1) TWI255716B (no)
UA (1) UA73937C2 (no)
WO (1) WO2000066144A2 (no)
ZA (1) ZA200108013B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202360B2 (en) * 2008-08-30 2016-03-24 Melinta Therapeutics, Inc. Methods of treatment using single doses of oritavancin
EP3006038B1 (en) * 2008-08-30 2024-07-03 The Medicines Company Single doses of oritavancin for treating or preventing a bacterial infection
CA2904387C (en) 2013-03-15 2021-12-07 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
PL3038616T3 (pl) * 2013-08-26 2023-08-07 Melinta Therapeutics, Inc. Metody leczenia bakteriemii i zapalenia kości i szpiku z zastosowaniem orytawancyny

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives

Also Published As

Publication number Publication date
AU774647B2 (en) 2004-07-01
KR20020008173A (ko) 2002-01-29
BR0010244A (pt) 2002-01-08
EA200101171A1 (ru) 2002-04-25
KR100757165B1 (ko) 2007-09-07
NO20015291D0 (no) 2001-10-29
TR200103211T2 (tr) 2002-02-21
IL145582A (en) 2008-12-29
WO2000066144A2 (en) 2000-11-09
HUP0200940A2 (en) 2002-08-28
HUP0200940A3 (en) 2002-10-28
HK1044707B (zh) 2005-09-30
DZ3039A1 (fr) 2004-03-27
DE60016734D1 (de) 2005-01-20
EP1175222B1 (en) 2004-12-15
NZ514467A (en) 2005-01-28
PE20010292A1 (es) 2001-03-07
CN1349407A (zh) 2002-05-15
CA2372790A1 (en) 2000-11-09
DE60016734T2 (de) 2005-12-08
SK285970B6 (sk) 2007-12-06
EA004295B1 (ru) 2004-02-26
HK1044707A1 (en) 2002-11-01
CZ296127B6 (cs) 2006-01-11
IL145582A0 (en) 2002-06-30
SV2002000065A (es) 2002-12-02
TWI255716B (en) 2006-06-01
ZA200108013B (en) 2003-03-26
PL353444A1 (en) 2003-11-17
AU4329200A (en) 2000-11-17
CZ20013949A3 (cs) 2002-07-17
AR023827A1 (es) 2002-09-04
MY123542A (en) 2006-05-31
SK15572001A3 (sk) 2003-05-02
JP2002543146A (ja) 2002-12-17
UA73937C2 (en) 2005-10-17
HRP20010808A2 (en) 2002-12-31
ATE284702T1 (de) 2005-01-15
WO2000066144A3 (en) 2001-04-12
EP1175222A2 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
ITRM930591A0 (it) Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
CA3188924A1 (en) Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
ATE219373T1 (de) Medikamente zur behandlung von autoimmunerkrankungen mit interferon-tau
DE69131014D1 (de) Rekombinante avirulente salmonella antifruchtbarkeitsimpfstoffe
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
DE69627147D1 (de) Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
DK0806941T3 (da) Liposomalt antibakterielt præparat med lav fasthed
MXPA05005338A (es) Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.
DK1059934T3 (da) Matrixproteinpræparater til sårheling
HK1068606A1 (en) Novel aminobenzoephenones
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
ATE259654T1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
DK0781560T3 (da) Anvendelse af immunoglobulinpræparater til fremstilling af et medikament til oral indgivelse til behandling og forebyggelse
GEP20063812B (en) Single dose azithromycin for treating respirator infections
NO20015291L (no) Månedlige doser for behandling av Streptococcus pneumoniae- infeksjoner
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application